Prevalence and clinical significance of electrocardiographic signs of atrial myopathy in rheumatoid arthritis: results from the EDRA study
Main finding · Atrial myopathy prevalenceResult — go to the resultOdds ratio 4.83 95% CI 1.58–14.73Authors' conclusion
Electrocardiographic markers of atrial myopathy are independently associated with RA.
Study context
- Population
- Rheumatoid arthritis (RA) patients and matched controls, all free from previous CVD and AF
- Participants
- 218 vs 109
- Exposure
- RA vs controls matched by age and gender
- RAn = 218
- Controlsn = 109reference
- Outcome
- Prevalence of ECG-defined atrial myopathy (aIAB, or pIAB plus abnormal PtfV1)
Methodological detailscontrols matched by age and gender, multiple regression, 5-year follow-up of RA patients
- Controls matched by age and gender
- Multiple regression
- 5-year follow-up of RA patients
Main finding
Atrial myopathy prevalence
Odds ratio
4.83
95% CI 1.58–14.73
P = 0.006
By group
RAvs Controls
OR 4.83 (95% CI 1.58–14.73); P = 0.006
As reported in the abstract
Observational data: associations, not effects.
Further findings
P-wave duration
P < 0.001
pIAB prevalence
P < 0.001
Abnormal PtfV1 prevalence
P < 0.001
Male gender and atrial myopathy (multiple regression)
- Male gender, OR [95% CI] 3.09 [1.48-6.47], p=0.003
Atrial myopathy and incident AF or cardiovascular events in RA · 5 years
- Not significantly associated
Original publication
Prevalence and clinical significance of electrocardiographic signs of atrial myopathy in rheumatoid arthritis: results from the EDRA study. Clin Exp Rheumatol. Published 9 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →